Patient Selection for Esaxerenone in Real-World Practice

Abstract

Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has emerged as a significant therapeutic option for patients with hypertension and chronic kidney disease (CKD), particularly in the context of proteinuria and diabetic nephropathy. This review synthesizes current evidence on patient selection for esaxerenone in real-world clinical practice, integrating recent clinical trial data and guideline-based recommendations. The article explores epidemiological trends, pathophysiological mechanisms, risk stratification, clinical features, diagnostic approaches, and the role of esaxerenone within the broader landscape of antihypertensive and renoprotective therapies. Special attention is given to practical considerations, emerging research, and future directions in optimizing patient outcomes with esaxerenone.

Introduction

Mineralocorticoid receptor antagonists (MRAs) have long been recognized for their role in managing resistant hypertension and providing renoprotective benefits in chronic kidney disease (CKD). Esaxerenone distinguishes itself from traditional steroidal MRAs by its high selectivity, potent binding affinity, and favorable safety profile, particularly regarding hyperkalemia risk. As real-world data accumulates, understanding which patient populations derive the most benefit from esaxerenone becomes crucial for clinicians aiming to implement evidence-based and individualized care. This review aims to consolidate current scientific knowledge and practical experience regarding patient selection for esaxerenone in routine clinical settings.

Epidemiology / Disease Burden

Hypertension remains a global public health challenge, affecting more than 1.2 billion adults worldwide, with a significant proportion demonstrating suboptimal control despite multiple antihypertensive agents. CKD, often comorbid with hypertension and diabetes mellitus, contributes to substantial morbidity, mortality, and healthcare costs. The prevalence of diabetic nephropathy continues to rise, paralleling increasing rates of type 2 diabetes. Proteinuria is an established marker of renal and cardiovascular risk, justifying aggressive management strategies. MRAs are underutilized in clinical practice due to concerns about adverse effects, yet they offer significant benefits in reducing proteinuria and slowing CKD progression. Esaxerenone, approved in Japan and under investigation globally, addresses an unmet need for more selective MRAs in high-risk populations.

Pathophysiology

The pathogenesis of hypertension and CKD is intricately linked to overactivation of the renin-angiotensin-aldosterone system (RAAS), with aldosterone exerting deleterious effects through mineralocorticoid receptor–mediated sodium retention, fibrosis, and vascular inflammation. In diabetic nephropathy, aldosterone excess promotes glomerulosclerosis and tubulointerstitial injury, accelerating renal function decline. Traditional steroidal MRAs, such as spironolactone and eplerenone, are limited by off-target effects and risk of hyperkalemia, especially in CKD. Esaxerenone acts as a highly selective, non-steroidal inhibitor of the mineralocorticoid receptor, attenuating aldosterone-driven pathology while minimizing hormonal and metabolic side effects.

Risk Factors

Candidates for esaxerenone therapy typically present with hypertension refractory to standard therapy, CKD with overt proteinuria, or diabetic nephropathy. Additional risk factors include a history of cardiovascular disease, left ventricular hypertrophy, and metabolic syndrome. The risk of hyperkalemia is highest in patients with advanced CKD (eGFR <30 mL/min/1.73 m²), poorly controlled diabetes, or those on concomitant RAAS inhibitors. Careful patient selection and monitoring are paramount to maximize benefits and mitigate risks.

Clinical Features

Patients suitable for esaxerenone generally exhibit persistent hypertension (often >140/90 mmHg) despite multidrug regimens, significant proteinuria (urinary albumin-to-creatinine ratio >30 mg/g), or early to moderate CKD (stages 1–3). Clinical features may include edema, left ventricular hypertrophy on echocardiography, and evidence of end-organ damage. In diabetic nephropathy, microalbuminuria or macroalbuminuria with progressive decline in eGFR are key indicators for MRAs. The absence of contraindications, such as severe hyperkalemia or hypersensitivity reactions, is essential before initiation.

Diagnosis

Diagnostic workup prior to initiating esaxerenone includes confirmation of hypertension via ambulatory or home blood pressure monitoring, assessment of renal function (serum creatinine and eGFR), evaluation of serum potassium, and quantification of proteinuria using spot or 24-hour urine collections. Screening for secondary causes of hypertension and exclusion of adrenal disorders is recommended, particularly in resistant cases. Baseline electrocardiogram and echocardiography may help assess cardiac involvement. Ongoing monitoring of renal and electrolyte parameters is recommended throughout treatment.

Treatment & Management

Esaxerenone is typically initiated at a low dose (1.25–2.5 mg daily) and titrated based on blood pressure response, proteinuria reduction, and tolerability. Dose adjustments are necessary in the setting of declining renal function or rising serum potassium (>5.0 mmol/L). Esaxerenone is often used in conjunction with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) to maximize renoprotection. Patient education regarding dietary potassium, adherence, and symptom recognition is essential. Regular laboratory monitoring (every 2–4 weeks initially, then less frequently) is critical to minimize adverse events.

Recent Advances / Emerging Therapies

Recent randomized controlled trials, including the ESCALATOR and ESAX-DN studies, have demonstrated esaxerenone’s efficacy in reducing albuminuria and blood pressure with a manageable safety profile in patients with diabetic nephropathy and CKD. Subgroup analyses suggest particular benefit in patients with high baseline proteinuria and early diabetic nephropathy. Emerging data indicate potential applications in heart failure with preserved ejection fraction (HFpEF) and non-diabetic CKD, expanding the therapeutic scope. Comparative effectiveness studies with finerenone and other novel MRAs are ongoing, aiming to delineate optimal patient selection and sequencing of therapy.

Guideline Recommendations

Japanese Society of Hypertension and Japanese Society of Nephrology guidelines endorse esaxerenone for patients with hypertension and proteinuric CKD, particularly those intolerant to steroidal MRAs. International guidelines increasingly recognize the role of non-steroidal MRAs, though regional availability may limit use. Consensus emphasizes individualized risk assessment, baseline renal function evaluation, and cautious dosing in advanced CKD or concomitant RAAS blockade. Shared decision-making, patient education, and vigilant monitoring remain foundational principles in guideline-based esaxerenone therapy.

Conclusion

Esaxerenone represents a significant advancement in the management of hypertension and proteinuric renal disease, offering efficacy and safety advantages over traditional MRAs. Appropriate patient selection—anchored in evidence-based criteria, clinical judgment, and guideline recommendations—is essential for optimizing outcomes. As real-world experience and clinical data continue to evolve, esaxerenone’s role is likely to expand, underscoring the importance of ongoing research, education, and multidisciplinary collaboration.